Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main objective of the study is to determine if implication of epoxy-eicosatriénoïc acids (EETs) and NO during cutaneous post-occlusive hyperemia differs between patients with Raynaud phenomena and healthy volunteers, by studying hyperaemic postocclusive response after microinjection of fluconazole and L-NMMA at the dorsal side of the fingers.
The main objective of the study is to determine if implication of epoxy-eicosatriénoïques acids (EETs) and NO during cutaneous post-occlusive hyperemia differs between patients with Raynaud phenomena and healthy volunteers, by studying hyperaemic postocclusive response after microinjection of fluconazole and L-NMMA at the dorsal side of the fingers.
Healthy controls and patients will undergo 3 visits
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Reynaud | Experimental | patients with reynaud phenomena |
|
| Healthy | Experimental | Healthy volunteers |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| post-occlusive hyperemia | Procedure |
| ||
| cooling box |
| Measure | Description | Time Frame |
|---|---|---|
| post occlusive hyperemia amplitude | post-occlusive hyperemia amplitude (maximal amplitude in % of maximal vasodilatation and AUC) in sites NaCl, fluconazole and L-NMMA (intradermal microinjection) | day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| post occlusive hyperemia amplitude with anesthetic treatment | post-occlusive hyperemia amplitude (maximal amplitude in % of maximal vasodilatation and AUC) in sites NaCl, fluconazole and L-NMMA (intradermal microinjection) treated with anesthetic | day1 |
| cold-induced vasoconstriction amplitude |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jean-Luc CRACOWSKI, MD-PhD | Contact | +33476769260 | JLCracowski@chu-grenoble.fr | |
| Matthieu ROUSTIT, PharmD-PhD | Contact | +33476769260 | MRoustit@chu-grenoble.fr |
| Name | Affiliation | Role |
|---|---|---|
| Jean-Luc CRACOWSKI, MD-PhD | INSERM + University Hospital Grenoble | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre d'investigation clinique CIC1406 | Recruiting | Grenoble Cedex9 | 38043 | France |
Not provided
| ID | Term |
|---|---|
| D011928 | Raynaud Disease |
| D006940 | Hyperemia |
| D003139 | Common Cold |
| ID | Term |
|---|---|
| D000090122 | Livedoid Vasculopathy |
| D013927 | Thrombosis |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D019323 | omega-N-Methylarginine |
| ID | Term |
|---|---|
| D001120 | Arginine |
| D024361 | Amino Acids, Basic |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Procedure |
|
| L-NMMA and Fluconazole dermic injection | Drug |
|
cold-induced vasoconstriction amplitude (maximal amplitude in % of basal and AUC) in sites NaCl, fluconazole and L-NMMA (intradermal microinjection) |
| day 2 |
| cold-induced vasoconstriction amplitude with anesthetic treatment | cold-induced vasoconstriction amplitude (maximal amplitude in % of basal and AUC) in sites NaCl, fluconazole and L-NMMA (intradermal microinjection) with anesthetic local treatment | day 2 |
| D002318 |
| Cardiovascular Diseases |
| D016491 | Peripheral Vascular Diseases |
| D017445 | Skin Diseases, Vascular |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D010850 | Picornaviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012140 | Respiratory Tract Diseases |
| D000599 |
| Amino Acids, Diamino |
| D000601 | Amino Acids, Essential |